RECRUITINGPhase 2INTERVENTIONAL
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye
About This Trial
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Who May Be Eligible (Plain English)
Who May Qualify:
- Be at least 18 years of age of either gender and any race.
- Provide written willing to sign a consent form and sign the HIPAA form.
- Be willing and able to follow all instructions and attend all study visits.
Who Should NOT Join This Trial:
- Use of any of the disallowed medications during the washout and study period.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Be at least 18 years of age of either gender and any race.
* Provide written informed consent and sign the HIPAA form.
* Be willing and able to follow all instructions and attend all study visits.
Exclusion Criteria:
* Use of any of the disallowed medications during the washout and study period.
Treatments Being Tested
DRUG
VSJ-110
ophthalmic solution
DRUG
Placebo
ophthalmic solution
Locations (5)
Vanda Investigational Site
Newport Beach, California, United States
Vanda Investigational Site
Andover, Massachusetts, United States
Vanda Investigational Site
Shelby, North Carolina, United States
Vanda Investigational Site
Memphis, Tennessee, United States
Vanda Investigational Site
Lynchburg, Virginia, United States